Solara Active Pharma Q1 Review - Comprehensive Approach In API, CRAMS To Drive Growth: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Solara Active Pharma Science Ltd. delivered an in line Q1 FY22 earnings, led by increased contribution from new products, ramp in other markets like Asia-Pacific, and healthy growth in the contract research and manufacturing services business.
The company has delivered a robust performance, with Ebitda margin/profit after tax growing to 24%/ Rs 2.2 billion in FY21 from 14%/Rs 380 million in FY18.
Solara Active Pharma further aims to achieve 25% revenue compound annual growth rate over FY21-25 through enhanced portfolio offering in generic active pharma ingredient, strong scale-up in the CRAMS segment, and the inorganic route.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.